Treatment of Patients With Castration Resistant Prostate Cancer Using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccine
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2018
At a glance
- Drugs ETBX- 071 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 26 Jul 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 31 Jul 2018 to 1 Aug 2018.
- 25 Jul 2018 Planned primary completion date changed from 1 Jun 2021 to 1 May 2021.